Open-label Study of Surufatinib in Japanese Patients

NCT05077384 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors
Non-hematologic Malignancy

Interventions

DRUG: Surufatinib

Sponsor

Hutchmed